EP1901820A4 - Method for reducing levels of disease associated proteins - Google Patents

Method for reducing levels of disease associated proteins

Info

Publication number
EP1901820A4
EP1901820A4 EP06737807A EP06737807A EP1901820A4 EP 1901820 A4 EP1901820 A4 EP 1901820A4 EP 06737807 A EP06737807 A EP 06737807A EP 06737807 A EP06737807 A EP 06737807A EP 1901820 A4 EP1901820 A4 EP 1901820A4
Authority
EP
European Patent Office
Prior art keywords
disease associated
associated proteins
reducing levels
levels
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06737807A
Other languages
German (de)
French (fr)
Other versions
EP1901820A2 (en
Inventor
Samuel T Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerecin Inc
Original Assignee
Accera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accera Inc filed Critical Accera Inc
Priority to EP16169037.5A priority Critical patent/EP3124090A1/en
Publication of EP1901820A2 publication Critical patent/EP1901820A2/en
Publication of EP1901820A4 publication Critical patent/EP1901820A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP06737807A 2005-05-03 2006-03-08 Method for reducing levels of disease associated proteins Withdrawn EP1901820A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16169037.5A EP3124090A1 (en) 2005-05-03 2006-03-08 Diets for reducing levels of disease associated proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/123,706 US20060252775A1 (en) 2005-05-03 2005-05-03 Methods for reducing levels of disease associated proteins
PCT/US2006/008668 WO2006118665A2 (en) 2005-05-03 2006-03-08 Method for reducing levels of disease associated proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP16169037.5A Division EP3124090A1 (en) 2005-05-03 2006-03-08 Diets for reducing levels of disease associated proteins

Publications (2)

Publication Number Publication Date
EP1901820A2 EP1901820A2 (en) 2008-03-26
EP1901820A4 true EP1901820A4 (en) 2012-08-29

Family

ID=37308436

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16169037.5A Withdrawn EP3124090A1 (en) 2005-05-03 2006-03-08 Diets for reducing levels of disease associated proteins
EP06737807A Withdrawn EP1901820A4 (en) 2005-05-03 2006-03-08 Method for reducing levels of disease associated proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16169037.5A Withdrawn EP3124090A1 (en) 2005-05-03 2006-03-08 Diets for reducing levels of disease associated proteins

Country Status (4)

Country Link
US (3) US20060252775A1 (en)
EP (2) EP3124090A1 (en)
JP (1) JP5819578B2 (en)
WO (1) WO2006118665A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
ES2323940T3 (en) 2000-05-01 2009-07-28 Accera, Inc. USE OF MEDIUM CHAIN TRIGLICERIDS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE.
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP2001293B9 (en) 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20080089981A1 (en) * 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
NZ599748A (en) 2007-06-26 2013-11-29 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
PT2650378E (en) 2007-07-31 2016-01-14 Accera Inc Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
CN101951923B (en) 2007-12-20 2013-10-30 N.V.努特里奇亚 Liquid nucleotides/nucleosides-containing product
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
CN105640931A (en) * 2008-07-03 2016-06-08 艾克塞拉公司 acetoacetic monoglyceride for treating neurotic disorder and derivative thereof
JP5704533B2 (en) * 2009-02-13 2015-04-22 国立大学法人大阪大学 Diagnostic method and diagnostic agent for Alzheimer's disease
EP2512514B1 (en) * 2009-12-14 2014-11-05 Kyoto University Screening method for identifying compounds for treating amyotrophic lateral sclerosis
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
EP2916655A4 (en) * 2012-11-12 2015-09-30 Nestec Sa Methods for determining if an animal's metabolism is ketogenic
EP3013371A4 (en) * 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
WO2015156865A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
EP3125904A4 (en) * 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
US20170202239A1 (en) 2014-07-17 2017-07-20 The Nisshin Oillio Group, Ltd. Baked confectionery that substantially includes no flour
WO2019013616A1 (en) 2017-07-12 2019-01-17 N.V. Nutricia Treatment of traumatic brain injury
CN108371712B (en) * 2018-01-18 2020-12-25 华北理工大学 Application of caffeine and PPAR gamma agonist in preparation of AD (active ingredients) medicaments in combination
JPWO2020255743A1 (en) * 2019-06-18 2020-12-24
CN113367327B (en) * 2021-06-03 2022-07-08 暨南大学 Application of ketogenic diet in preventing herpes simplex virus encephalitis
CN113481221A (en) * 2021-08-27 2021-10-08 黑龙江八一农垦大学 Coding gene SOD in blood related to milk cow ketosis and PCR detection kit thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207011A2 (en) * 1985-06-11 1986-12-30 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980A (en) * 1848-12-19 Machinery fob turning irbegttlab shapes
US2017520A (en) * 1929-06-20 1935-10-15 Rca Corp Glow discharge device such as is used in the recording of sound
US2766146A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766145A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) * 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
JPS53105517A (en) * 1977-02-28 1978-09-13 Hoya Glass Works Ltd Fluorophosphate laser glass
DE2717916C3 (en) * 1977-04-22 1980-06-12 Jenaer Glaswerk Schott & Gen., 6500 Mainz Glasses with a small non-linear refractive index, especially for laser technology
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
JPS55144448A (en) * 1979-04-24 1980-11-11 Nippon Kogaku Kk <Nikon> Fluorophosphate optical glass
FR2490631A1 (en) * 1980-09-24 1982-03-26 Roussel Uclaf NOVEL LIPID COMPOSITION FOR USE IN DIETETICS, REANIMATION AND THERAPEUTICS
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) * 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) * 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE3843238C1 (en) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5412804A (en) * 1992-04-30 1995-05-02 Oracle Corporation Extending the semantics of the outer join operator for un-nesting queries to a data base
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE625212T1 (en) * 1992-10-13 2000-11-02 Univ Durham METHOD FOR DISCOVERING DISEASE OF ALZHEIMER.
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
US6963920B1 (en) * 1993-11-19 2005-11-08 Rose Blush Software Llc Intellectual asset protocol for defining data exchange rules and formats for universal intellectual asset documents, and systems, methods, and computer program products related to same
US5600831A (en) * 1994-02-28 1997-02-04 Lucent Technologies Inc. Apparatus and methods for retrieving information by modifying query plan based on description of information sources
US5724567A (en) * 1994-04-25 1998-03-03 Apple Computer, Inc. System for directing relevance-ranked data objects to computer users
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
JP4179641B2 (en) * 1994-10-31 2008-11-12 株式会社住田光学ガラス Fluorophosphate fluorescent glass containing Tb or Eu
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP3961585B2 (en) * 1995-11-21 2007-08-22 株式会社住田光学ガラス Fluorophosphate fluorescent glass with visible fluorescence
KR100192233B1 (en) * 1995-11-30 1999-06-15 구자홍 Deflection yoke for cathode ray tube
JP4598203B2 (en) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド Brain function improver
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
DE19609476A1 (en) * 1996-03-11 1997-09-18 Basf Ag Stable parenteral administration suitable carotenoid emulsions
KR980008239A (en) * 1996-07-26 1998-04-30 김충환 Cyclosporin-containing pharmaceutical composition
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
ES2530753T3 (en) * 1997-03-17 2015-03-05 Btg Int Ltd Therapeutic compositions comprising ketone bodies and precursors thereof
US6460034B1 (en) * 1997-05-21 2002-10-01 Oracle Corporation Document knowledge base research and retrieval system
US20040058873A1 (en) 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US7152031B1 (en) * 2000-02-25 2006-12-19 Novell, Inc. Construction, manipulation, and comparison of a multi-dimensional semantic space
US6295092B1 (en) * 1998-07-30 2001-09-25 Cbs Corporation System for analyzing television programs
AU6039199A (en) * 1998-09-14 2000-04-03 Pan Pacific Pharmaceuticals, Inc. Useful properties of a bee venom protein and gene encoding same
US6645228B2 (en) * 2001-11-13 2003-11-11 Playtex Products, Inc. Nipple
US6711585B1 (en) * 1999-06-15 2004-03-23 Kanisa Inc. System and method for implementing a knowledge management system
US6732080B1 (en) * 1999-09-15 2004-05-04 Nokia Corporation System and method of providing personal calendar services
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2323940T3 (en) * 2000-05-01 2009-07-28 Accera, Inc. USE OF MEDIUM CHAIN TRIGLICERIDS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE.
US7653530B2 (en) * 2000-07-13 2010-01-26 Novell, Inc. Method and mechanism for the creation, maintenance, and comparison of semantic abstracts
US7286977B1 (en) * 2000-09-05 2007-10-23 Novell, Inc. Intentional-stance characterization of a general content stream or repository
DE20012857U1 (en) * 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gm Dietary food for fat loss
JP4405661B2 (en) * 2000-11-22 2010-01-27 富士通株式会社 Reservation server, user terminal, reservation system, and reservation method
US7117198B1 (en) * 2000-11-28 2006-10-03 Ip Capital Group, Inc. Method of researching and analyzing information contained in a database
WO2002098398A1 (en) * 2001-06-07 2002-12-12 Eisai Co., Ltd. Methods for preventing and treating diseases and conditions associated with cellular stress
US6931399B2 (en) * 2001-06-26 2005-08-16 Igougo Inc. Method and apparatus for providing personalized relevant information
US20030059824A1 (en) * 2001-09-21 2003-03-27 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
US7192897B2 (en) * 2002-07-05 2007-03-20 Hoya Corporation Near-infrared light-absorbing glass, near-infrared light-absorbing element, near-infrared light-absorbing filter, and method of manufacturing near-infrared light-absorbing formed glass article, and copper-containing glass
US7320806B2 (en) * 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
US6884454B2 (en) * 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
US7103609B2 (en) * 2002-10-31 2006-09-05 International Business Machines Corporation System and method for analyzing usage patterns in information aggregates
US20040122841A1 (en) * 2002-12-19 2004-06-24 Ford Motor Company Method and system for evaluating intellectual property
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7617202B2 (en) * 2003-06-16 2009-11-10 Microsoft Corporation Systems and methods that employ a distributional analysis on a query log to improve search results
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
WO2006007194A1 (en) * 2004-06-25 2006-01-19 Personasearch, Inc. Dynamic search processor
US8078607B2 (en) * 2006-03-30 2011-12-13 Google Inc. Generating website profiles based on queries from webistes and user activities on the search results
DE102004038727A1 (en) * 2004-08-10 2006-02-23 Schott Ag Method and device for producing hybrid lenses
JP4570576B2 (en) * 2005-03-30 2010-10-27 Ｈｏｙａ株式会社 Optical glass, press-molding preform and manufacturing method thereof, and optical element and manufacturing method thereof
JP4498315B2 (en) * 2005-07-28 2010-07-07 Ｈｏｙａ株式会社 Optical glass, optical element and manufacturing method thereof
US7577665B2 (en) * 2005-09-14 2009-08-18 Jumptap, Inc. User characteristic influenced search results
JP5160043B2 (en) * 2006-03-31 2013-03-13 Ｈｏｙａ株式会社 Glass material for mold press and method for producing glass optical element
EP2001293B9 (en) * 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
JP5079273B2 (en) * 2006-07-03 2012-11-21 Ｈｏｙａ株式会社 Phosphate glass, fluorophosphate glass, precision press-molding preform, optical element and manufacturing method thereof
US7613692B2 (en) * 2006-07-25 2009-11-03 Microsoft Corporation Persona-based application personalization
JP2008137877A (en) * 2006-12-05 2008-06-19 Hoya Corp Optical glass and optical element
US10007895B2 (en) * 2007-01-30 2018-06-26 Jonathan Brian Vanasco System and method for indexing, correlating, managing, referencing and syndicating identities and relationships across systems
US8060505B2 (en) * 2007-02-13 2011-11-15 International Business Machines Corporation Methodologies and analytics tools for identifying white space opportunities in a given industry
JP5410270B2 (en) * 2007-03-06 2014-02-05 Ｈｏｙａ株式会社 Optical glass, press-molding preform, optical element and manufacturing method thereof
US20080235189A1 (en) * 2007-03-23 2008-09-25 Drew Rayman System for searching for information based on personal interactions and presences and methods thereof
US20090063467A1 (en) * 2007-08-30 2009-03-05 Fatdoor, Inc. Persona management in a geo-spatial environment
JP5069649B2 (en) * 2008-03-28 2012-11-07 Ｈｏｙａ株式会社 Fluorophosphate glass, precision press-molding preform, optical element blank, optical element and production method thereof
JP5115984B2 (en) * 2008-03-28 2013-01-09 Ｈｏｙａ株式会社 Fluorophosphate glass, glass material for press molding, optical element blank, optical element and respective manufacturing methods
US8285070B2 (en) * 2008-04-07 2012-10-09 The Trustees Of Tufts College Methods and apparatus for image restoration
JP5188269B2 (en) * 2008-05-30 2013-04-24 Ｈｏｙａ株式会社 Optical glass, glass material for press molding, optical element blank, optical element, and production method thereof
US7870253B2 (en) * 2008-10-01 2011-01-11 The Cobalt Group, Inc. Systems and methods for aggregating user profile information in a network of affiliated websites

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207011A2 (en) * 1985-06-11 1986-12-30 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AN TANGHE ET AL: "Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model", INTERNATIONAL JOURNAL OF ALZHEIMER'S DISEASE, vol. 155, no. 6, 1 January 2010 (2010-01-01), pages 2153 - 9, XP055282184, DOI: 10.1006/nbdi.1998.0183 *

Also Published As

Publication number Publication date
US20100034745A1 (en) 2010-02-11
EP3124090A1 (en) 2017-02-01
US20130005693A1 (en) 2013-01-03
JP2008542200A (en) 2008-11-27
WO2006118665A3 (en) 2008-12-18
JP5819578B2 (en) 2015-11-24
EP1901820A2 (en) 2008-03-26
US20060252775A1 (en) 2006-11-09
WO2006118665A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
EP1901820A4 (en) Method for reducing levels of disease associated proteins
EP1748077A4 (en) Method of producing protein
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
GB0823478D0 (en) Method of cementing
IL188781A (en) Method of improving synchronization
IL190550A0 (en) Methods of protein production using anti-senescence compounds
EP1855729A4 (en) Method of sterilization
ZA200600495B (en) Method of treatment for improved bioavailability
EP1919477A4 (en) Method of improving wakefulness
GB0422004D0 (en) Method of deprotection
EP1869230A4 (en) Method for purifying proteins
EP1964538A4 (en) Preparation method of pharmaceutials
EP1947453A4 (en) Method for analyzing protein
IL179901A0 (en) Process for protein isolation
ZA200700167B (en) Process for protein isolation
EP1760149A4 (en) Method of constructing modified protein
PL1934388T3 (en) Method of drug design
TWI347975B (en) Method of producing recombinant protein
EP1882743A4 (en) Method for producing protein
EP1739089A4 (en) Method of separating protein
ZA200800590B (en) Method of improving wakefulness
GB0427827D0 (en) Method of diagnosis
EP1854811A4 (en) Assay method for human orotate phosphoribosyltransferase protein
HU0401136D0 (en) Method for post-blinding of gas-plumbing
GB0419567D0 (en) Method of imaging

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20081218

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/401 20060101ALI20090109BHEP

Ipc: A61K 31/522 20060101ALI20090109BHEP

Ipc: A63D 15/00 20060101AFI20090109BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUERA PHARMACEUTICALS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ACCERA, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20120726

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101ALI20120720BHEP

Ipc: A63D 15/00 20060101AFI20120720BHEP

Ipc: A61K 31/401 20060101ALI20120720BHEP

17Q First examination report despatched

Effective date: 20130927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160708